46 studies found for:    "Zollinger-Ellison Syndrome"
Show Display Options
Rank Status Study
21 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
22 Recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
23 Active, not recruiting Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: cixutumumab;   Drug: octreotide acetate;   Drug: everolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis
24 Recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
25 Not yet recruiting Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: dovitinib lactate;   Other: pharmacological study;   Other: laboratory biomarker analysis
26 Recruiting MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Somatostatinoma;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: TORC1/2 inhibitor MLN0128;   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
27 Active, not recruiting Capecitabine and Temozolomide for Neuroendocrine Cancers
Condition: Neuroendocrine Tumors
Intervention: Drug: Capecitabine and temozolomide
28 Completed
Has Results
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Condition: Healthy
Interventions: Drug: Clopidogrel;   Drug: Clopidogrel and Lansoprazole;   Drug: Clopidogrel and Dexlansoprazole;   Drug: Clopidogrel and Omeprazole;   Drug: Clopidogrel and Esomeprazole
29 Completed Cinacalcet to Treat Familial Primary Hyperparathyroidism
Conditions: Hypercalcemia;   Familial Primary Hyperparathyroidism
Interventions: Procedure: Parathyroid hormone testing;   Procedure: Serum calcium testing
30 Active, not recruiting Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome;   Neuroendocrine Tumor
Interventions: Biological: bevacizumab;   Drug: 5-fluorouracil;   Drug: leucovorin;   Drug: oxaliplatin
31 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
32 Completed Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome
Intervention: Drug: thalidomide
33 Completed Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Condition: Cancer
Interventions: Biological: trastuzumab;   Drug: tipifarnib
34 Terminated Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Conditions: Brain and Central Nervous System Tumors;   Childhood Langerhans Cell Histiocytosis;   Gastrointestinal Carcinoid Tumor;   Head and Neck Cancer;   Intraocular Melanoma;   Islet Cell Tumor;   Kidney Cancer;   Lung Cancer;   Melanoma (Skin);   Neoplastic Syndrome;   Neuroendocrine Carcinoma of the Skin;   Pheochromocytoma
Intervention: Radiation: indium In 111 pentetreotide
35 Completed EPO906 in Carcinoid and Other Neuroendocrine Tumors
Conditions: Carcinoid;   Neuroendocrine Tumors
Intervention: Drug: EPO906 epothilone B
36 Unknown  AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: motesanib diphosphate;   Drug: octreotide acetate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Procedure: computed tomography
37 Completed
Has Results
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Condition: Cancer
Interventions: Drug: Fentanyl sublingual spray;   Drug: Placebo
38 Terminated Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Conditions: Head and Neck Cancer;   Islet Cell Tumor;   Metastatic Cancer;   Pheochromocytoma
Interventions: Drug: octreotide acetate;   Radiation: yttrium Y 90 resin microspheres
39 Completed Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
Condition: Cancer
Interventions: Drug: floxuridine;   Drug: leucovorin calcium;   Drug: oxaliplatin
40 Unknown  Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-46) Show next page of results
Indicates status has not been verified in more than two years